For the quarter ending 2026-03-31, ELVN has $464,852K in assets. $11,487K in debts. $132,184K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 132,184 | 98,896 | 101,732 | 119,437 |
| Marketable securities | 320,217 | 363,725 | 375,833 | 371,066 |
| Restricted cash | - | 0 | 0 | 0 |
| Prepaid expenses and other current assets | 10,736 | 12,257 | 5,118 | 5,119 |
| Total current assets | 463,137 | 474,878 | 482,683 | 495,622 |
| Property and equipment, gross | - | - | 1,535 | - |
| Less accumulated depreciation | - | - | 1,136 | - |
| Property and equipment, net | 20 | 34 | 399 | 462 |
| Operating lease right-of-use assets | 290 | 383 | 475 | 564 |
| Deferred offering costs | 217 | 217 | 217 | - |
| Other long-term assets | 1,188 | 656 | 7,101 | 7,239 |
| Total assets | 464,852 | 476,168 | 490,875 | 503,887 |
| Accounts payable | 1,640 | 2,159 | 1,429 | 2,351 |
| Accrued expenses and other current liabilities | 9,847 | 14,409 | 13,221 | 12,860 |
| Total current liabilities | 11,487 | 16,568 | 14,650 | 15,211 |
| Long-term liabilities | - | - | 103 | 204 |
| Total liabilities | 11,487 | 16,568 | 14,753 | 15,415 |
| Common stock, par value 0.001 authorized shares - 100,000,000 issued and outstanding shares - 60,889,655 and 59,440,045 at march 31, 2026 and december 31, 2025, respectively | 61 | 59 | 59 | 59 |
| Additional paid-in capital | 824,479 | 806,373 | 793,341 | 785,941 |
| Accumulated other comprehensive (loss) income | -382 | 334 | 221 | -177 |
| Accumulated deficit | -370,793 | -347,166 | -317,499 | -297,351 |
| Total stockholders' equity | 453,365 | 459,600 | 476,122 | 488,472 |
| Total liabilities and stockholders' equity | 464,852 | 476,168 | 490,875 | 503,887 |
Enliven Therapeutics, Inc. (ELVN)
Enliven Therapeutics, Inc. (ELVN)